MBRX Share Price | Moleculin Biotech, Inc. Stock Analysis & Recommendation

Q: What does Moleculin Biotech, Inc. do?

Overview: Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the treatment of cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) Market cap: USD 9.41 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -7.59 Return on Equity: -3,695.30% Price to Book: 9.41Contact Details: Address: 5300 Memorial Dr Ste 950, HOUSTON TX: 77007-8274 Tel: 1 713 3005160 Website: http://www.moleculin.com/

Q: Is Moleculin Biotech, Inc. technically bullish or bearish?

As of 14 August 2025, the technical trend for Moleculin Biotech, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven primarily by the daily moving averages indicating bearish momentum. While the weekly MACD and KST show mildly bullish signals, the overall indicators, including Bollinger Bands and the daily moving averages, suggest weakness in the trend. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -75.76% compared to the benchmark's 12.22%.

Results Declared: Moleculin Biotech, Inc. has declared results on 18 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

70.87 k

Shareholding (Dec 2025)

FII

0.20%

Held by 7 FIIs

DII

99.01%

Held by 1 DIIs

Promoter

0.00%

How big is Moleculin Biotech, Inc.?

22-Jun-2025

As of Jun 18, Moleculin Biotech, Inc. has a market capitalization of 9.41 million and reported net sales of 0.00 million with a net profit of -23.23 million over the last four quarters. The balance sheet shows shareholder's funds of 5.98 million and total assets of 16.93 million.

View full answer

What does Moleculin Biotech, Inc. do?

22-Jun-2025

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on cancer treatments, with a market cap of $9.41 million and a recent net profit of -$6 million. The company operates in the Pharmaceuticals & Biotechnology industry and has no dividend yield or positive earnings.

View full answer

Is Moleculin Biotech, Inc. technically bullish or bearish?

20-Sep-2025

As of August 14, 2025, Moleculin Biotech, Inc. has shifted to a mildly bearish trend, with daily moving averages indicating bearish momentum and a year-to-date return of -75.76%, significantly underperforming the S&P 500's 12.22%.

View full answer

Compare Moleculin Biotech, Inc. with Similar Stocks

Eiger BioPharmaceuticals, Inc.Scorpius Holdings, Inc.Mangoceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 10 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.24

Return on Equity

167.81%

Price to Book

-0.38

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

16 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-49.4%

6 Months

-80.46%

1 Year

92.66%

2 Years

-98.53%

3 Years

-99.41%

4 Years

-99.65%

5 Years

-99.86%

Moleculin Biotech, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-3.19%

EBIT to Interest (avg)

-24.60

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-7.59

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.38

EV to EBIT

-0.15

EV to EBITDA

-0.15

EV to Capital Employed

-0.11

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (0.79%)

Foreign Institutions

Held by 7 Foreign Institutions (0.2%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 921.05% vs 81.55% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.50",
          "val2": "-6.60",
          "chgp": "-13.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "23.10",
          "val2": "4.70",
          "chgp": "391.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "15.60",
          "val2": "-1.90",
          "chgp": "921.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -29.23% vs 12.75% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.00",
          "val2": "-26.50",
          "chgp": "5.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-33.60",
          "val2": "-26.00",
          "chgp": "-29.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-7.50

-6.60

-13.64%

Interest

0.00

Exceptional Items

23.10

4.70

391.49%

Consolidate Net Profit

15.60

-1.90

921.05%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 921.05% vs 81.55% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-25.00

-26.50

5.66%

Interest

0.00

Exceptional Items

-8.50

0.00

Consolidate Net Profit

-33.60

-26.00

-29.23%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -29.23% vs 12.75% in Dec 2024

All Annual Results

Company CV

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

Pharmaceuticals & Biotechnology

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of cancers. Its clinical stage drug candidates include Annamycin, WP1066, WP1220, WP1732, WP1122 and WP1234. Annamycin is intended for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. WP1066 is an immune/transcription modulator (p-STAT3 inhibitor) and is intended to target a wide range of tumors, including brain tumors and pancreatic cancer. WP1220 is intended for the topical treatment of cutaneous T-cell lymphoma (CTCL). WP1732 is evaluated for the potential treatment of AML, pancreatic and other cancers. WP1122 and WP1234 are evaluated for the potential to treat brain tumors and pancreatic cancer through its ability to inhibit glycolysis. It is also engaged in development of drug candidates, including additional immune/transcription modulators, as well as metabolism/glycosylation inhibitors.

Company Coordinates

Company Details

5300 Memorial Dr Ste 950 , HOUSTON TX : 77007-8274

Tel: 1 713 3005160

http://www.moleculin.com/

Registrar Details